43 results
8-K
EX-99.2
LUMO
Lumos Pharma Inc
7 Mar 24
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
4:44pm
to advancing the PGHD program into Phase 3 Year 2023 Year 2022 R&D Expense $22.1M $17.9M G&A Expense $16.6M $15.7M Net Loss $34.0M $31.1M Cash, Cash
8-K
EX-99.1
LUMO
Lumos Pharma Inc
7 Mar 24
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
4:44pm
. Cash on hand as of December 31, 2023 is expected to support operations through the third quarter of 2024.
R&D Expenses – Research and development
8-K
EX-99.1
LUMO
Lumos Pharma Inc
7 Nov 23
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
4:42pm
of the activities related to planning and initiation of a pivotal Phase 3 clinical trial.
R&D Expenses – Research and development expenses were $5.0
8-K
EX-99.1
LUMO
Lumos Pharma Inc
9 Aug 23
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
4:36pm
of our second quarter 2023 financial statements.
Exhibit 99.1
R&D Expenses – Research and development expenses increased by $1.4 million for the three
8-K
EX-99.1
6jd2vhgz
3 May 23
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates
4:49pm
8-K
EX-99.1
js1l7bhwtbnex1xu2qg
14 Nov 22
Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates
7:29am
8-K
EX-99.2
b783l4xxo536s
14 Nov 22
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
6:55am
8-K
EX-99.1
o9k9za6yh4w7n hjcz
10 Aug 22
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates
12:00am
8-K
EX-99.1
lm2xumz
10 May 22
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
4:47pm
8-K
EX-99.1
uj8 mcdva6kmxhp
10 Mar 22
Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials
4:20pm
8-K
EX-99.1
02dnz604
3 Nov 21
Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates
4:11pm
8-K
EX-99.2
ncsgo94acnxw
5 Aug 21
Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
4:27pm
8-K
EX-99.1
hb4k2b9v
5 Aug 21
Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
4:27pm
8-K
EX-99.1
ddkmmcru2t2
5 May 21
Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
4:28pm
8-K
EX-99.1
glvfr2
9 Mar 21
Lumos Pharma Reports Full Year 2020 Financial Results and Provides Update on OraGrowtH Trials in PGHD
4:26pm
8-K
EX-99.1
s5a 4dt6avi9p09b0t
10 Nov 20
Lumos Pharma Announces the Initiation of Phase 2b OraGrowtH210 Trial and Reports Third Quarter 2020 Financial Results
4:31pm
8-K
EX-99.1
s7dup457ctxlela0
13 Aug 20
Lumos Pharma Reports Second Quarter 2020 Results and Provides Update on Clinical and Corporate Activities
4:36pm